Table 3 Differences in post-occlusive reactive hyperemia between OSA and non-OSA groups

Resting ∆[Hbtot] (AU)

−0.49 ± 3.3

−1.22 ± 3.6

0.835

End Occlusion ∆[Hbtot] (AU)

−7.47 ± 4.9

−7.89 ± 3.8

0.902

Post Occlusion ∆[Hbtot] Max (AU)

4.28 ± 4.9

10.51 ± 4.6

0.007*

∆[Hbtot] ΔC_RH

10.95 ± 5.1

18.41 ± 5.1

0.024*

∆[Hbtot] ΔC_OCC

−6.62 ± 3.5

−7.01 ± 2.4

0.723

∆[Hbtot] MHR (%)

150.88 ± 16.2

227.78 ± 72.7

0.006*

∆[Hbtot] tM (seconds)

80.46 ± 13.1

47.69 ± 9.9

0.002*

Resting ∆[HbO₂] (AU)

−0.108 ± 2.4

−0.943 ± 2.4

0.489

End Occlusion ∆[HbO₂] (AU)

−13.64 ± 3.6

−17.21 ± 5.7

0.011*

Post Occlusion ∆[HbO₂] Max (AU)

4.63 ± 3.4

8.84 ± 6.1

0.079

∆[HbO₂] ΔC_RH

18.27 ± 4.3

26.06 ± 11.1

0.016*

∆[HbO₂] ΔC_OCC

−13.15 ± 3.1

−16.53 ± 6.9

0.029*

∆[HbO₂] MHR (%)

131.4 ± 8

161.7 ± 10.6

0.001*

∆[HbO₂] tM (s)

85.15 ± 22.4

52.08 ± 5.9

0.001*